Inhalation of urokinase-type plasminogen activator reduces airway remodeling in a murine asthma model

被引:31
作者
Kuramoto, Emi
Nishiuma, Teruaki
Kobayashi, Kazuyuki
Yamamoto, Masatsugu
Kono, Yuko
Funada, Yasuhiro
Kotani, Yoshikazu
Sisson, Thomas H. [2 ]
Simon, Richard H. [2 ]
Nishimura, Yoshihiro [1 ]
机构
[1] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Resp Med,Chuo Ku, Kobe, Hyogo 6500017, Japan
[2] Univ Michigan, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI USA
关键词
urokinase; plasmin; bronchial asthma; subepithelial fibrosis; HEPATOCYTE GROWTH-FACTOR; INDUCED PULMONARY-FIBROSIS; INDUCED LUNG FIBROSIS; TGF-BETA; INFLAMMATION; INHIBITOR-1; EXPRESSION; COLLAGEN; MICE; ACCUMULATION;
D O I
10.1152/ajplung.90434.2008
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Kuramoto E, Nishiuma T, Kobayashi K, Yamamoto M, Kono Y, Funada Y, Kotani Y, Sisson TH, Simon RH, Nishimura Y. Inhalation of urokinase-type plasminogen activator reduces airway remodeling in a murine asthma model. Am J Physiol Lung Cell Mol Physiol 296: L337-L346, 2009. First published December 19, 2008; doi: 10.1152/ajplung.90434.2008.-The airway remodeling that occurs in asthma is characterized by an excess of extracellular matrix deposition in the submucosa, hyperplasia/hypertrophy of smooth muscle, goblet cell metaplasia, and accumulation of fibroblasts/myofibroblasts. he urokinase-type plasminogen activator (uPA)/plasmin system participates in pericellular proteolysis and is capable of directly degrading matrix components, activating latent proteinases, and activating growth factors. In a mouse ovalbumin (OVA) asthma model, we increased plasminogen activator activity in the lung by administering exogenous uPA or by using mice genetically deficient in the uPA inhibitor plasminogen activator inhibitor-1 (PAI-1) to assess the role of this system in asthma pathogenesis. After intraperitoneal OVA sensitization, mice inhaled OVA plus uPA (500 IU/mouse) or saline by ultrasonic nebulization for 3 wk. When studied 24 h after the final exposure, the groups with upregulated plasmin activity had significantly reduced subepithelial fibrosis within the airway walls and had decreased airway hyperresponsiveness (AHR) to methacholine. Morphometric analysis showed that subepithelial wall thickening of the bronchi (subepithelial area ratio) was also reduced, as were collagen and alpha-smooth muscle actin. Upregulation of plasmin activity also increased the level of hepatocyte growth factor activity in bronchoalveolar lavage fluid, whereas the release of transforming growth factor-beta was decreased. The administration of uPA 1 wk after the last OVA inhalation also significantly reduced lung hydroxyproline content and AHR. These results show that enhancing uPA/plasmin activity lessens the airway remodeling in a murine asthma model.
引用
收藏
页码:L337 / L346
页数:10
相关论文
共 50 条
  • [41] MODULATION OF THE MALIGNANT PHENOTYPE WITH THE UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND THE TYPE-I PLASMINOGEN-ACTIVATOR INHIBITOR
    SORDAT, B
    REITER, L
    CAJOT, JF
    CELL DIFFERENTIATION AND DEVELOPMENT, 1990, 32 (03): : 277 - 286
  • [42] Urokinase-type plasminogen activator receptor is associated with the development of adipose tissue
    Kanno, Yosuke
    Matsuno, Hiroyuki
    Kawashita, Eri
    Okada, Kiyotaka
    Suga, Hidetaka
    Ueshima, Shigeru
    Matsuo, Osamu
    THROMBOSIS AND HAEMOSTASIS, 2010, 104 (06) : 1124 - 1132
  • [43] What is the Role of Soluble Urokinase-Type Plasminogen Activator in Renal Disease?
    Saleem, Moin A.
    NEPHRON, 2018, 139 (04) : 334 - 341
  • [44] Levels of Components of the Urokinase-type Plasminogen Activator System are Related to Chronic Obstructive Pulmonary Disease Parenchymal Destruction and Airway Remodelling
    Zhang, Y.
    Xiao, W.
    Jiang, Y.
    Wang, H.
    Xu, X.
    Ma, D.
    Chen, H.
    Wang, X.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2012, 40 (03) : 976 - 985
  • [45] Delivering urokinase-type plasminogen activator using mulberry leaf exosomes enables thrombolysis and remodeling of venous microenvironments
    Guan, Pengpeng
    Yuan, Caijie
    Li, Jiali
    Yu, Kun
    Xie, Ruiqi
    Hu, Enling
    Ding, Weiwei
    Lan, Guangqian
    Lu, Fei
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 282
  • [46] Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer
    Knoop, A
    Andreasen, PA
    Andersen, JA
    Hansen, S
    Lænkholm, AV
    Simonsen, ACW
    Andersen, J
    Overgaard, J
    Rose, C
    BRITISH JOURNAL OF CANCER, 1998, 77 (06) : 932 - 940
  • [47] Downregulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 by grape seed proanthocyanidin extract
    Sandra, Dhungana
    Radha, Madhyastha
    Harishkumar, Madhyastha
    Yuichi, Nakajima
    Sayuri, Omura
    Masugi, Maruyama
    PHYTOMEDICINE, 2010, 17 (01) : 42 - 46
  • [48] FIBRINOLYTIC PROPERTIES OF SINGLE CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (PRO-UROKINASE)
    DEMUNK, GAW
    RIJKEN, DC
    FIBRINOLYSIS, 1990, 4 (01) : 1 - 9
  • [49] Amino-terminal fragment of urokinase-type plasminogen activator inhibits its plasminogen activation
    Sun, ZY
    Zhang, PX
    Wang, P
    Gurewich, V
    Shen, HY
    Liu, JN
    THROMBOSIS RESEARCH, 2002, 106 (02) : 105 - 111
  • [50] Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation
    Gupta, Kamlesh K.
    Donahue, Deborah L.
    Sandoval-Cooper, Mayra J.
    Castellino, Francis J.
    Ploplis, Victoria A.
    SCIENTIFIC REPORTS, 2017, 7